MIM
EIGR

Monashee Investment Management’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Monashee Investment Management’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-1,050
Closed -$362K – 75
2016
Q4 		$367K Buy
+1,050
New +$385K 0.18% 74
2016
Q3 		– Hold
0
– – – 68
2016
Q2 		– Hold
0
– – – 13
2016
Q1 		– Hold
0
– – – 13

Other funds holding EIGR

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Monashee Investment Management's EIGR Position: Q1 2017 in Review

Monashee Investment Management sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q1 2017, closing a stake of 1,050 shares — an estimated $362K sold.

Monashee Investment Management first reported a position in EIGR in Q4 2016 and held it in 1 quarter. The position peaked at $367K in Q4 2016. 45 funds tracked by Wall St. Rank hold EIGR as of Q1 2017.

  • Monashee Investment Management reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
  • Monashee Investment Management sold 1,050 Eiger BioPharmaceuticals, Inc. shares in Q1 2017, an estimated $362K.
  • Monashee Investment Management first reported a position in Eiger BioPharmaceuticals, Inc. in Q4 2016 and held it in 1 quarter.
  • Monashee Investment Management's Eiger BioPharmaceuticals, Inc. position peaked at $367K in Q4 2016.
  • 45 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q1 2017.

Based on Monashee Investment Management's 13F filing for Q1 2017, filed 12 May 2017.